SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
SB497115 is an oral agent which activates the thrombopoietin receptor and increases platelet
counts in healthy volunteers. This study is examining several different doses of SB497115
versus placebo as treatment for patients with advanced solid tumors scheduled to receive
chemotherapy with carboplatin and paclitaxel every 21 days. Patients will receive SB497115 on
days 2-11 of each 21 day cycle for at least 2 cycles of chemotherapy and for a maximum of 8
cycles of chemotherapy.